Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy.

To assess the impact of cribriform pattern and/or intraductal carcinoma (IDC) on Gleason 7 prostate cancer (PCa) treated with external beam radiotherapy (EBRT).

We evaluated men with Gleason 7 (Grade Group 2 and 3) PCa treated with dose-escalated EBRT +/- androgen deprivation, and reviewed biopsies for the presence of cribriform pattern and/or IDC. Endpoints included biochemical recurrence free survival (BRFS), distant metastasis free survival (DMFS), and disease specific survival (DSS).

Of 237 patients, median follow up was 117 months (range 3-236), and NCCN risk group was 24% favorable-intermediate risk, 53% unfavorable-intermediate risk, and 23% high risk. Rates of cribriform pattern without IDC, cribriform pattern with IDC, IDC without cribriform pattern, and neither morphology, were 36%, 13%, 0%, and 51%, respectively. On multivariable analysis (MVA), presence of cribriform pattern with IDC (HR 4.22; 95% CI 2.08-8.53; p<0.0001), PSA 10-20 ng/ml (1.97; 1.03-3.79; p=0.04), and PSA >20 ng/ml (2.26; 1.21-4.23; p=0.01) were associated with worse BRFS. On MVA, only cribriform pattern with IDC was associated with inferior DMFS (4.18; 1.43-12.28; p=0.01) and DSS (14.26; 2.75-74.04; p=0.0016). Factors associated with having cribriform pattern +/- IDC included Grade Group 3, high risk group, and ≥50% positive biopsy cores. When stratified by neither morphology present, cribriform pattern without IDC, and cribriform pattern with IDC, differences in BRFS (p=0.00042), DMFS (p=0.017), and DSS (p<0.0001) were statistically significant.

Cribriform pattern with IDC was associated with adverse outcomes among men with Gleason 7 PCa treated with ERBT, whereas cribriform pattern without IDC was not. Future studies may benefit from dichotomizing these two histologic entities.

The Journal of urology. 2019 May 06 [Epub ahead of print]

Martin C Tom, Jane K Nguyen, Roberta Lucianò, Omar Y Mian, Kevin L Stephans, Jay P Ciezki, Timothy D Smile, Wei Wei, Jesse K McKenney, Cristina Magi-Galluzzi, Rahul D Tendulkar

Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic , Cleveland , OH., Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic , Cleveland , OH., Department of Pathology, IRCCS San Raffaele Scientific Institute , Milan , Italy., Taussig Cancer Institute, Cleveland Clinic , Cleveland , OH., Department of Pathology, University of Alabama at Birmingham School of Medicine , Birmingham , AL.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.